

The Use of Tobramycin in Two Formulations in the Treatment of Bacterial Conjunctivitis and Bacterial Corneal Ulcers

Y. Maychuk¹, E. Mironkova¹, D. Maychuk²

¹ *Infectious Diseases, Helmholtz Institute of Ophthalmology,* ² *Training, Eye Diseases, Fedorov Institute, Moscow, Russia*

Purpose: To demonstrate the superiority of Tobrex 2X[®] (enhanced viscosity eye drops) over Tobrex[®].

Patients and methods: 94 patients were included in the study. 56 diagnosed with bacterial conjunctivitis were assigned (1:1) to receive treatment with Tobrex 4 to 6 times daily or Tobrex 2X, 2 to 3 times daily. 40 patients diagnosed with bacterial keratitis (corneal ulcer) were assigned (1:1) to receive Tobrex by fortified method or Tobrex 2X 4 to 6 times daily.

Results: out of a total of 94 patients enrolled in the study, 48 with conjunctivitis and 38 with keratitis were culture positive. Therapy with both treatments was effective in the majority of the cases, including all cases of Pseudomonas Aeruginosa corneal ulcers.

Conclusions: Tobramycin enhanced viscosity ophthalmic solution (Tobrex 2X) is well tolerated and has equivalent efficacy to tobramycin ophthalmic solution (Tobrex) in the treatment of bacterial keratitis and demonstrated the superiority to improve patients compliance and satisfaction.